GAL-021

GAL-021 is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel,[1] although secondary mechanisms may also be involved.[2] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care,[3] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs.[4][5][6]

GAL-021
Clinical data
Routes of
administration		IV
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC11H22N6O
Molar mass254.331 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. McLeod, JF; Leempoels, JM; Peng, SX; Dax, SL; Myers, LJ; Golder, FJ (November 2014). "GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers" (PDF). British Journal of Anaesthesia. 113 (5): 875–83. doi:10.1093/bja/aeu182. PMID 24989775.
  2. Baby, SM; Hoshi, T; Peng, S; Dax, SL; Golder, FJ; MacIntyre, DE; Mannion, JC (2012). "Comparison of the respiratory effects of GAL-021 in BK α subunit knockout (Slo1−/−) and wild-type mice". The FASEB Journal. 26 (1 Supplement): 704.30. doi:10.1096/fasebj.26.1_supplement.704.30 (inactive 2019-08-21).
  3. Golder, FJ; Hewitt, MM; McLeod, JF (1 November 2013). "Respiratory stimulant drugs in the post-operative setting". Respiratory Physiology & Neurobiology. 189 (2): 395–402. doi:10.1016/j.resp.2013.06.010. PMID 23791825.
  4. Baby, SM; Gruber, RB; Puskovic, V; Peng, S; Dax, SL; Golder, FJ; MacIntyre, DE; Mannion, JC (2012). "GAL-021, a novel respiratory stimulant, attenuates opioid–induced respiratory depression without compromising analgesia". The FASEB Journal. 26 (1 Supplement): 704.28. doi:10.1096/fasebj.26.1_supplement.704.28 (inactive 2019-08-21).
  5. van der Schier, R; Roozekrans, M; van Velzen, M; Dahan, A; Niesters, M (4 September 2014). "Opioid-induced respiratory depression: reversal by non-opioid drugs". F1000Prime Reports. 6: 79. doi:10.12703/P6-79. PMC 4173639. PMID 25343036.
  6. Roozekrans, M; van der Schrier, R; Okkerse, P; Hay, J; McLeod, JF; Dahan, A (September 2014). "Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers". Anesthesiology. 121 (3): 459–68. doi:10.1097/ALN.0000000000000367. PMID 25222672.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.